Skip to content

Evaluation of an Early Management Strategy for Obstructive Sleep Apnea

Evaluation of an Early Management Strategy for Obstructive Sleep Apnea: A Randomized Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04613414
Enrollment
103
Registered
2020-11-03
Start date
2022-06-24
Completion date
2025-12-31
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Keywords

Access to Health Care, Time to Treatment, Treatment Adherence, Quality of Care

Brief summary

The primary objective of this study is to evaluate the effect of more timely care for obstructive sleep apnea (OSA) on adherence to positive airway pressure (PAP) therapy at three months after treatment initiation. The secondary objectives are to determine if earlier care improves the treatment effect of PAP on patient reported sleepiness, quality of life and patient satisfaction. We will also evaluate the impact of shorter wait times on patient engagement in therapy by assessing initial acceptance of PAP therapy, patient activation and self-efficacy with respect to OSA treatment. The study hypothesis is that the early management strategy will be superior to usual care with respect to the primary outcome of PAP adherence at three months.

Interventions

OTHEREarly Management

Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage

Sponsors

University of Calgary
Lead SponsorOTHER
Canadian Lung Association
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HSAT ODI \>= events/hr and ESS 10 - 15 OR * HSAT ODI 15 - 30 and ESS 15 or lower

Exclusion criteria

* Severe nocturnal hypoxemia on HSAT (mean oxygen saturation by pulse oximetry (SpO2) ≤ 85%) * Severe hypersomnolence (Epworth Sleepiness Scale score ≥ 16) * Employed in safety-critical occupation * Recent motor vehicle collision reported on screening questionnaire (within one year) * Severe hypertension requiring ≥ three antihypertensive medications * Recent admission to hospital due to unstable cardiopulmonary disease (within 30 days) * Upcoming major surgery (within six months) * Prior history of OSA treatment * Significant co-morbid sleep disorder that would interfere with PAP acclimatization and adherence (e.g., severe insomnia, restless leg syndrome)

Design outcomes

Primary

MeasureTime frameDescription
Positive airway pressure adherence3 months after treatment initiationMean number of hours of positive airway pressure use per night in the four weeks prior to three month follow-up

Secondary

MeasureTime frameDescription
Positive airway pressure therapy initiation1 week after sleep physician visitProportion of patients who initiate positive airway pressure therapy
Adherent to positive airway pressure3 months after treatment initiationProportion of patients using positive airway pressure therapy for at least four hours per night on at least 70% of nights during the four weeks prior to the three-month follow-up
Sleepiness3 months after treatment initiationChange in Epworth Sleepiness Scale score from baseline to three months. Scale is from 0-24 with higher scores indicating greater sleepiness
General health-related quality of life: Change in EuroQoL-5D-3L3 months after treatment initiationChange in EuroQoL-5D-3L index score (0-1, higher scores indicating greater quality of life), dimensions (problem vs no problem) and visual analogue score (0-100, higher score indicating greater quality of life) from baseline to three months
Disease-specific health-related quality of life: Change in Sleep Apnea Quality of Life Index3 months after treatment initiationChange in Sleep Apnea Quality of Life Index from baseline to three months. Scale includes four domains scored from 1-7, with higher scores indicating greater quality of life. The overall score is the average from the four domains
Patient satisfaction: Visit-Specific Satisfaction Instrument total score3 months after treatment initiationVisit-Specific Satisfaction Instrument total score compared between groups at baseline and after three months of PAP therapy. Scale includes 9 questions rated from 1-5. Total score is between 9-45 with higher scores indicating greater satisfaction
Patient activation3 months after treatment initiationChange in Patient Activation Measure score from baseline to three months. Scale is from 0-100 with higher scores indicating greater activation
Patient activation level3 months after treatment initiationChange in patient activation level (based on Patient Activation Measure) from baseline to three months. Scale is from 0-100. Participants are classified from activation level 1-4 based on overall score, with higher level indicating greater activation
Self-efficacy: Self-Efficacy Measure for Sleep Apnea score3 months after treatment initiationSelf-Efficacy Measure for Sleep Apnea score compared between groups at baseline and after three months of PAP therapy. There are 3 subscales (risk perception, outcome expectancies, treatment self-efficacy), each scored from 1-4 with higher scores indicating greater self-efficacy

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORSachin Pendharkar

University of Calgary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026